Chapter 20. Media Directory. Amyotrophic Lateral Sclerosis. Alzheimer s Disease. Huntington s Chorea. Multiple Sclerosis

Similar documents
Nursing Process Focus: Patients Receiving Levodopa (Larodopa)

Introductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs

Drugs Affecting the Central Nervous System

475 GERIATRIC PSYCHOPHARMACOLOGY (p.1)

Drug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology

DRUG TREATMENT OF PARKINSON S DISEASE. Mr. D.Raju, M.pharm, Lecturer

Drug Management of Parkinsonism. By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.)

DRUGS THAT ACT IN THE CNS

LESSON ASSIGNMENT. Cholinergic Blocking Agents (Anticholinergic Agents).

Nursing Process Focus: Patients Receiving Chlorpromazine (Thorazine)

Drugs used in Parkinsonism

Drugs for Emotional and Mood Disorders Chapter 16

Treatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS

History Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson

Prior Authorization with Quantity Limit Program Summary

Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.

parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to

PARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease

Treatment of Parkinson s Disease: Present and Future

Aricept, Exelon and Reminyl the new drugs for Alzheimer s disease

Neurodegenerative diseases

Alzheimer s Disease. Pathophysiology: Alzheimer s disease (AD) is a progressive dementia affecting cognition, behavior,

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits

Presenter. Dr. Ronald Lucchino

Parkinson s Disease Current Treatment Options

Optimizing Clinical Communication in Parkinson s Disease:

WHEN THE GOING GETS TOUGH: Working Through the Challenges of Dementia Together. Presented by

VL VA BASAL GANGLIA. FUNCTIONAl COMPONENTS. Function Component Deficits Start/initiation Basal Ganglia Spontan movements

10th Medicine Review Course st July Prakash Kumar

Parkinson s Pharmacology

Biology 3201 Nervous System # 7: Nervous System Disorders

Qualitative and Quantitative Composition

Parkinson s Disease. Sirilak yimcharoen

Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai

Parkinson s Disease. Prevalence. Mark S. Baron, M.D. Cardinal Features. Clinical Characteristics. Not Just a Movement Disorder

DISORDERS OF THE MOTOR SYSTEM. Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine

Extrapyramidal Motor System. Basal Ganglia or Striatum. Basal Ganglia or Striatum 3/3/2010

Parkinson s Disease and Its Treatment

Margo J Nell Dept Pharmacology

Evaluation of Parkinson s Patients and Primary Care Providers

Parkinson s Disease Medications: Professionals Edition

The Person: Dementia Basics

Memory Loss, Dementia and Alzheimer's Disease: The Basics

Pathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)

PARKINSON S MEDICATION

First described by James Parkinson in his classic 1817 monograph, "An Essay on the Shaking Palsy"

Understanding Dementia

7/3/2013 ABNORMAL PSYCHOLOGY SEVENTH EDITION CHAPTER FOURTEEN CHAPTER OUTLINE. Dementia, Delirium, and Amnestic Disorders. Oltmanns and Emery

DATA SHEET 1 PRODUCT NAME. Benztropine Omega 1mg/ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Program Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York

Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist

Identification number: TÁMOP /1/A

Chapter 17. Psychoses. Classifications of Psychoses. Schizophrenia. Factors Attributed to Development of Psychoses

DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

Resources: Types of dementia

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory KEMADRIN TABLETS. Procyclidine Tablets IP 2.

Best Medical Treatments for Parkinson s disease

Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE

The symptoms of the Parkinson s disease may vary from person to person. The symptoms might include the following:

The PD You Don t See: Cognitive and Non-motor Symptoms

Clinical Features and Treatment of Parkinson s Disease

Nursing Process Focus: Patients Receiving Bethanechol (Urecholine)

XADAGO (safinamide) oral tablet

Medications and the I/DD Population

BENZATROPINE (benz-a-tro-peen)

Parkinson s Disease Initial Clinical and Diagnostic Evaluation. J. Timothy Greenamyre, MD, PhD

If you have dementia, you may have some or all of the following symptoms.

Pharmacy Drug Class Review

Instruct patient and caregivers: Need for constant monitoring Potential complications of drug therapy

Tricyclic Antidespressants: Actions

ALZHEIMER S DISEASE. Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey

Alzheimer s Disease. Fact Sheet. Fact Sheet. Fact Sheet. What Causes AD?

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.

Parkinson s Disease Update

What is dementia? alzheimers.org.uk

Cheyenne 11/28 Neurological Disorders II. Transmissible Spongiform Encephalopathy

Medication Management & Strategies When the levodopa honeymoon is over

PARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada

The Role of Pharmacists in Treating & Managing Parkinson s Disease Author: Mary Jo Carden, RPh, JD Principal, Carden Associates

Dementia. Assessing Brain Damage. Mental Status Examination

Basal ganglia Sujata Sofat, class of 2009

Movement Disorders. Psychology 372 Physiological Psychology. Background. Myasthenia Gravis. Many Types

Case Study 2: Neurological Degenerative Disease FDA Regulatory and Clinical Background

Medications are Additive (Anticholinergic) Diane W. Healey, M.D. Center for Healthy Aging March 10, 2017

NMG-NEUROLOGY Dr. Bega, Dr. Malkani, Dr. Melen, Dr. Opal, Dr. Simuni, and Dr. Zadikoff MEDICAL BACKGROUND AND INFORMATION FORM

Test Bank for Essentials of Psychiatric Mental Health Nursing 1st Edition by Varcarolis

Antidepressants: Prof. Riyadh Al_Azzawi F.R.C.Psych

Pal Riba, M.D., Ph.D. Department of Pharmacology and Pharmacotherapy Semmelweis University, Budapest, Hungary November 7, 2017

Package Leaflet: Information for the User. Kemadrin tablets 5 mg procyclidine hydrochloride

Medications used to treat Parkinson s disease

Parkinson s Disease: initial diagnosis, initial treatment & non-motor features. J. Timothy Greenamyre, MD, PhD

These drugs produce effects similar to the sympathetic nervous system

Alzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer s is the most common form of dementia.

Transcription:

Chapter 20 Drugs for Degenerative Diseases of the Nervous System Slide 18 Media Directory Levadopa Animation Upper Saddle River, New Jersey 07458 All rights reserved. Alzheimer s Disease Amyotrophic Lateral Sclerosis Most common degenerative disease of CNS Progressive loss of brain function Memory loss, confusion, dementia Progressive weakness and wasting of muscles Destruction of motor neurons Huntington s Chorea Multiple Sclerosis Autosomal dominant genetic disorder Progressive dementia Involuntary, spasmodic movements Muscles of limbs and face affected Demyelination of neurons in CNS Progressive weakness, visual disturbances Mood alterations, cognitive deficits 1

Parkinson s Disease Second most common CNS disease Progressive loss of dopamine Tremor, muscle rigidity Abnormal movement and posture Tremors Muscle rigidity Bradykinesia Postural instability Symptoms of Parkinson s Disease Cause of Symptoms Neurotransmitters Degeneration and destruction of dopamine-producing neurons Substantia nigra portion of brain Corpus striatum Normally controls unconsciousness muscle movement Dopamine and acetylcholine in corpus striatum Affect balance, posture Affect muscle tone, involuntary movement Absence of dopamine Allows acetylcholine stimulation Drug Therapy for Parkinsonism Restores dopamine function Blocks acetylcholine Role of the Nurse: Dopaminergic Drug Therapy Contraindicated in narrow-angle glaucoma Monitor for hypotension and tachycardia Look for symptoms of drug toxicity 2

Dopaminergics Client Teaching Anticholinergics Client Teaching Increase fiber and fluids Avoid food and drugs high in pyridoxine May take several months for full effect Abruptly stopping the drug may cause Parkinsonism crisis Relieve dry mouth with frequent drinks or sugarless hard candy Take with food or milk to prevent GI upset Avoid alcohol Wear dark glasses; avoid bright sunlight Do not stop taking abruptly Nursing Considerations with AChE Inhibitors Assess baseline vitals Monitor for hypotension Monitor for change in mental status or mood Monitor for dizziness, insomnia, anorexia Clients with narrow-angle glaucoma should not take revastigmine (Exelon) AChE Inhibitors Client Teaching Take with food or milk to avoid GI upset Take as prescribed Teach signs and symptoms of overdose Severe nausea/vomiting, sweating, salivation, hypotension Bradycardia, convulsions, increased muscle weaknesses (including respiratory muscles) Dopaminergic Agents Levadopa Animation Prototype drug: levodopa (Larodopa) Mechanism of action: restore functional balance of dopamine and acetylcholine in corpus striatum Primary use: inhibit enzymes that destroy levodopa or directly activate dopamine receptor in the brain Adverse effects: nausea/vomiting, dyskinesias, postural hypotension, psychosis, dark urine and sweat, activation of malignant melanoma Click here to view an animation on the topic of levadopa. Back to Directory 3

Anticholinergic Agents Prototype drug: benztropine mesylate (Cogentin) Mechanism of action: block acetylcholine; inhibit overactivity in brain Primary use: in early stages of disease Adverse effects: dry mouth, blurred vision, photophobia, urinary retention, constipation, tachycardia, glaucoma Acetylcholinesterase (AChE) Inhibitors Prototype drug: donepezil hydrochloride (Aricept) Mechanism of action: to prevent breakdown of acetylcholine; enhance transmission in neurons Primary use: slow progression of the disease Adverse effects: nausea/vomiting, dizziness and headache, bronchoconstriction, liver injury (tacrine/cognex) Alzheimer s Disease (AD) Cause unknown Possible causes Genetic defects Chronic inflammation Excess free radicals Environmental factors Structural Damage in Brain Consists of Amyloid plaques Neurofibrillary tangles Changes found during autopsies Structural changes cause loss of neuron number and function Symptoms result from progressive damage to neurons in hippocampus Requires acetylcholine as neurotransmitter Symptoms of Alzheimer s Disease Impaired memory and judgment Confusion and disorientation Inability to recognize family and friends Aggressive behavior Depression Anxiety and psychoses Goals of Pharmacotherapy for Alzheimer s Disease Slow memory loss Slow dementia symptoms Improve activities of daily living Improve behavior Improve cognition 4

Efficacy of Drug Therapy No cure Moderate efficacy All drugs have equal efficacy Ineffective in late stages New drugs under investigation Medications given as adjunct therapy Acetylcholinesterase (AchE) Inhibitors For Alzheimer s disease Prevent breakdown of acetylcholine Enhances transmission in cholinergic neurons Only slow progression AchE Inhibitor Examples Dopaminergics Donepezil hydrochloride (Aricept) Galantamine (Reminyl) Tacrine (Cognex) Rivastigmine tartrate (Exelon) For Parkinson s disease Restore balance of dopamine and acetylcholine Dopaminergic examples Levodopa (Larodopa), Levodopa and carbidopa (Sinemet) Dopaminergic Adjunct Agents Anticholinergic Agents Inhibit enzymes Activate dopamine receptors Dopaminergic adjunct examples Ropinirole (Requip) Bromocriptine (Parlodel) For Parkinson s disease Centrally acting Block acetylcholine Inhibits overactivity in brain Used in early stages 5

Anticholinergics Examples Benztropine mesylate (Cogentin) Triexyphenidyl hydrochloride (Artane) Drugs for Degenerative Diseases of the Nervous System Assessment Complete health and drug history Assess severity of disease Monitor vital signs and lab tests Assess client/family knowledge of disease Nursing Diagnoses Risk for falls Deficient knowledge related to drug therapy Deficient knowledge related to disease process Impaired physical mobility Self-care deficit Constipation Planning Goals Increased ease of movement Decrease in symptoms Understanding of drug regimen/disease Adherence to drug regimen Reporting of side effects Implementation Monitor vital signs and lab tests Ensure client safety Monitor behavior changes Observe for symptoms of overdose Monitor for improved functional status Monitor for drug side effects Evaluation Effectiveness of drug therapy Client goals/outcomes met 6

Dopaminergic Drugs Used for Parkinsonism Anticholinergics & Parkinsonism Table 20.2 Dopaminergic Drugs Used for Parkinsonism Table 20.3 Anticholinergics & Parkinsonism Acetylcholinesterase Inhibitors for Alzheimer s Disease Table 20.4 Acetylcholinesterase Inhibitors for Alzheimer s Disease 7